TICKERNOMICS Sign up
Last Update: 2024-12-27 15:21:27
BOSTON SCIENTIFIC CORP ( BSX ) https://www.bostonscientific.com
91.30USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
BSX
62.49%
SPY
32.66%
BSX
111.49%
SPY
108.59%
BSX
102.23%
SPY
302.52%
BSX
583.99%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
135792.18
144405.73
2.60
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
75.90
8.54
6.60
1.60
0.00
43.31
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
17.42
68.83
20.34
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.7056
7.16
9.04
0.92
Other Earnings and Cash Flow Stats:
BOSTON SCIENTIFIC CORP ( BSX ) Net Income TTM ($MM) is 1789.00
BOSTON SCIENTIFIC CORP ( BSX ) Operating Income TTM ($MM) is 2512.00
BOSTON SCIENTIFIC CORP ( BSX ) Owners' Earnings Annual ($MM) is 0.00
BOSTON SCIENTIFIC CORP ( BSX ) Current Price to Owners' Earnings ratio is 0.00
BOSTON SCIENTIFIC CORP ( BSX ) EBITDA TTM ($MM) is 3469.00
BOSTON SCIENTIFIC CORP ( BSX ) EBITDA Margin is 20.34%
Capital Allocation:
BOSTON SCIENTIFIC CORP ( BSX ) has paid 0.00 dividends per share and bought back -12.4 million shares in the past 12 months
BOSTON SCIENTIFIC CORP ( BSX ) has increased its debt by 1582.0 million USD in the last 12 months
Capital Structure:
BOSTON SCIENTIFIC CORP ( BSX ) Interest-bearing Debt ($MM) as of last quarter is 10885
BOSTON SCIENTIFIC CORP ( BSX ) Annual Working Capital Investments ($MM) are 1426
BOSTON SCIENTIFIC CORP ( BSX ) Book Value ($MM) as of last quarter is 20610
BOSTON SCIENTIFIC CORP ( BSX ) Debt/Capital as of last quarter is 52%
Other Balance Sheet Stats:
BOSTON SCIENTIFIC CORP ( BSX ) has 2502 million in cash on hand as of last quarter
BOSTON SCIENTIFIC CORP ( BSX ) has 5910 million of liabilities due within 12 months, and long term debt 10567 as of last quarter
BOSTON SCIENTIFIC CORP ( BSX ) has 1487 common shares outstanding as of last quarter
BOSTON SCIENTIFIC CORP ( BSX ) has 0 million USD of preferred stock value
Academic Scores:
BOSTON SCIENTIFIC CORP ( BSX ) Altman Z-Score is 5.78 as of last quarter
BOSTON SCIENTIFIC CORP ( BSX ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
BOSTON SCIENTIFIC CORP ( BSX ) largest shareholder is owning shares at 0.00 ($MM) value
Carruthers Wendy(an insider) Sold 6983 shares of BOSTON SCIENTIFIC CORP ( BSX ) for the amount of $633916.74 on 2024-12-02
0.18% of BOSTON SCIENTIFIC CORP ( BSX ) is held by insiders, and 92.85% is held by institutions
BOSTON SCIENTIFIC CORP ( BSX ) went public on 1992-05-18
Other BOSTON SCIENTIFIC CORP ( BSX ) financial metrics:
FCF:1825.00
Unlevered Free Cash Flow:0.00
EPS:1.26
Operating Margin:17.42
Gross Profit Margin:68.83
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:9.04
Beta:0.92
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BOSTON SCIENTIFIC CORP ( BSX ) :
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.